Mainz Biomed (NASDAQ:MYNZ) Trading Down 3.5% – Here’s What Happened

Mainz Biomed NV (NASDAQ:MYNZ) dropped 3.5% during mid-day trading on Tuesday . The stock traded as low as $1.3503 and last traded at $1.39. 511,983 shares were traded during mid-day trading, an increase of 38% from the average session volume of 371,589 shares. The stock had previously closed at $1.44.

Mainz Biomed Trading Down 4.7%

The company has a debt-to-equity ratio of 0.44, a current ratio of 0.52 and a quick ratio of 0.43. The company’s 50 day moving average is $1.51 and its two-hundred day moving average is $1.21. The firm has a market cap of $11.82 million, a P/E ratio of -0.02 and a beta of 0.31.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MYNZ. Armistice Capital LLC increased its position in shares of Mainz Biomed by 96.5% during the 4th quarter. Armistice Capital LLC now owns 775,263 shares of the company’s stock worth $868,000 after purchasing an additional 380,744 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its position in Mainz Biomed by 200.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock valued at $34,000 after buying an additional 20,000 shares in the last quarter. Finally, Cerity Partners LLC bought a new stake in Mainz Biomed during the fourth quarter worth about $183,000.

Mainz Biomed Company Profile

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.